MARKET

DARE

DARE

Dare Bioscience Inc
NASDAQ
0.8902
-0.0298
-3.24%
Closed 19:37 12/07 EST
OPEN
0.9125
PREV CLOSE
0.9200
HIGH
0.9199
LOW
0.8900
VOLUME
211.56K
TURNOVER
--
52 WEEK HIGH
2.510
52 WEEK LOW
0.8803
MARKET CAP
75.51M
P/E (TTM)
-2.4632
1D
5D
1M
3M
1Y
5Y
BRIEF-Dare Bioscience Inc Says On Dec. 1, 2022, Co Received Grant Payment Of About $4.4 Mln From Bill & Melinda Gates Foundation
Reuters · 2d ago
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga · 6d ago
JonesTrading Initiates Coverage On Dare Bioscience with Buy Rating, Announces Price Target of $6
Benzinga · 12/01 09:55
--JonesTrading Starts Dare Bioscience at Buy With $6 Price Target
--JonesTrading Starts Dare Bioscience at Buy With $6 Price Target
MT Newswires · 12/01 07:54
Georgia Supreme Court Reinstates State's Ban On Abortions After Roughly Six Weeks Of Pregnancy
Benzinga · 11/23 17:00
Abortion Opponents Sue FDA And HHS, Seeking To Reverse Abortion Pill's Approval; Lawsuit Also Seeks To Undo FDA Decisions Easing Access To Mifepristone
Benzinga · 11/18 18:42
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 11/15 17:00
Daré gets Gates Foundation grant to develop Hydrogel tech for use in vaginal health
Seekingalpha · 11/15 14:28
More
About DARE
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health. Its portfolio of differentiated therapies expands treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Its product pipeline includes three product candidates in advanced stages of clinical development, three in Phase I clinical development and three in pre-clinical stage development. The product candidates in its pipeline include DARE-BV1, Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-FRT1, DARE-VVA1, DARE-LARC1, ORB-204 and ORB-214, and DARE-RH1. DARE-BV1 is focused on the treatment for bacterial vaginosis. Ovaprene is designed to provide multiple weeks of contraceptive protection and Sildenafil Cream, 3.6% is for the treatment of female sexual arousal disorders are under advanced stages of clinical development.

Webull offers kinds of Dare Bioscience Inc stock information, including NASDAQ:DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.